AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX) EVP Nikita Shah Sells 50,000 Shares

Key Points

• EVP Nikita Shah of Amneal Pharmaceuticals sold 50,000 shares for a total of $452,000, reducing their ownership stake by 12.86%.
• Amneal's stock recently experienced an upward movement, trading at $9.40 with a market capitalization of $2.95 billion.
• Analysts have given Amneal Pharmaceuticals an average rating of "Buy" with a consensus target price of $11.60.

AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX - Get Free Report) EVP Nikita Shah sold 50,000 shares of AMNEAL PHARMACEUTICALS stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $9.04, for a total transaction of $452,000.00. Following the transaction, the executive vice president directly owned 338,929 shares of the company's stock, valued at approximately $3,063,918.16. This trade represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Nikita Shah also recently made the following trade(s):

• On Thursday, August 14th, Nikita Shah sold 71,694 shares of AMNEAL PHARMACEUTICALS stock. The shares were sold at an average price of $9.29, for a total transaction of $666,037.26.

AMNEAL PHARMACEUTICALS Price Performance

AMRX traded down $0.09 on Monday, hitting $9.37. 234,676 shares of the stock were exchanged, compared to its average volume of 1,686,029. AMNEAL PHARMACEUTICALS, INC. has a 12 month low of $6.68 and a 12 month high of $9.59. The business has a 50-day moving average of $8.21 and a two-hundred day moving average of $7.97. The firm has a market capitalization of $2.94 billion, a price-to-earnings ratio of 937.44 and a beta of 1.11.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a negative return on equity of 189.49% and a net margin of 0.12%. Equities research analysts expect that AMNEAL PHARMACEUTICALS, INC. will post 0.53 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on AMRX. Wall Street Zen cut shares of AMNEAL PHARMACEUTICALS from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, May 13th. The Goldman Sachs Group assumed coverage on shares of AMNEAL PHARMACEUTICALS in a research report on Friday, June 6th. They issued a "buy" rating and a $12.00 target price for the company. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $11.60.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC increased its position in AMNEAL PHARMACEUTICALS by 5,975.0% during the 1st quarter. GAMMA Investing LLC now owns 3,159 shares of the company's stock valued at $26,000 after purchasing an additional 3,107 shares during the period. Headlands Technologies LLC acquired a new stake in AMNEAL PHARMACEUTICALS during the 1st quarter valued at approximately $31,000. Amalgamated Bank increased its position in AMNEAL PHARMACEUTICALS by 33.0% during the 1st quarter. Amalgamated Bank now owns 5,511 shares of the company's stock valued at $46,000 after purchasing an additional 1,367 shares during the period. GF Fund Management CO. LTD. acquired a new stake in AMNEAL PHARMACEUTICALS during the 4th quarter valued at approximately $52,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in AMNEAL PHARMACEUTICALS by 16.7% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,107 shares of the company's stock valued at $98,000 after purchasing an additional 1,735 shares during the period. Institutional investors and hedge funds own 31.82% of the company's stock.

About AMNEAL PHARMACEUTICALS

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.